Therapeutic effect of FLUVAR® for COVID-19

Efficacy evaluation of FLUVAR® in the onset of the disease with symptoms of respiratory infection synonymous with the symptoms of COVID-19 in patients referred to emergency departments and clinics

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200404046932N1

Enrollment

100

Registered

2021-10-14

Start date

2020-05-21

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19 disease

Interventions

Intervention 1: Intervention group 1- First intervention stage: Care and treatment based on standard protocol + Receiving single dose (5 ml) of FLUVAR® using a Pari Master nebulizer connected to the p

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 years and older Signing informed consent Possessing two distinct respiratory signs of COVID-19 O2Sat below 94% or positive signs on CT scan or positive PCR result for COVID-19

Exclusion criteria

Exclusion criteria: History of moderate or severe respiratory asthma Participating in another clinical trial for COVID-19

Design outcomes

Primary

Measure	Time frame
O2sat difference one hour post intervention. Timepoint: One hour after the intervention. Method of measurement: Pulse oximeter instrument.	—

Secondary

Measure	Time frame
Dyspnea scale. Timepoint: One hour after the intervention. Method of measurement: By Visual Analogue Scale questionnaire (VAS).;Intervention side effects. Timepoint: From the beginning to one day after the end of the intervention. Method of measurement: Observation and interview questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSayyed Ali Alavi

Hakiman e Shargh Research Co.

Sayyedalialavi@gmail.com+98 31 3667 1780

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026